Genomics
PrivateBest-in-class human proof for epigenetic editing (every FSHD patient gained lean muscle, no DNA cut), but a single-asset private racing three better-funded RNA/antibody rivals to a ~$600M market it will reach last — a platform-validation bet, not yet a franchise.
Research
The verdict
Best-in-class human proof for epigenetic editing (every FSHD patient gained lean muscle, no DNA cut), but a single-asset private racing three better-funded RNA/antibody rivals to a ~$600M market it will reach last — a platform-validation bet, not yet a franchise.
Epic Bio is a South San Francisco epigenetic-editing biotech (43 employees ) built around one idea: change what a gene does without changing the DNA sequence. It was founded in 2022 by Stanford bioengineer Stanley Qi — a Jennifer Doudna–lineage CRISPR pioneer and named co-inventor on the Nobel-Prize CRISPR patent held by the University of California, and the inventor of CRISPRa/CRISPRi — and launched publicly with a $55M Series A.
The product is a platform, not (yet) a drug. The Gene Expression Modulation System (GEMS) couples three parts: (1) a catalytically dead DNA-binding protein — Epic's differentiator is CasMINI, exclusively licensed, "the smallest and most deliverable noncutting Cas protein to work in human cells"; (2) a customizable guide RNA; (3) an epigenetic modulator payload that can silence, activate, or silence-and-replace a target gene. Because the machinery is hypercompact, the entire cassette fits inside one AAV vector — the packaging constraint that has historically blocked CRISPR-based in-vivo delivery.
How it makes money (eventually): two paths. (a) Wholly-owned rare-disease therapeutics — lead asset EPI-321 for FSHD, now in the clinic. (b) Platform licensing — a Kite/Gilead research-collaboration-and-license deal (Oct 2023) applies GEMS to modulate genes in Kite-selected CAR-T targets; Epic took an undisclosed upfront + is eligible for development/regulatory/sales milestones + tiered royalties. Contract structure: classic pre-revenue biotech — no take-or-pay, no recurring revenue, no customer concentration because there are no customers yet. Revenue today is effectively zero; the "customers" are (i) FSHD patients in a Phase 1/2 trial and (ii) one pharma partner (Kite) funding option-value.
+clinical re-point)For a one-time AAV gene therapy the "supply chain" is the manufacturing + delivery stack, and it is a genuine chokepoint:
n/a — private, not disclosed). This is the classic gene-therapy cost-of-goods and scale-up risk.Named chokepoints: (1) CasMINI license (single-source IP); (2) GMP AAV capacity (CDMO); (3) AAV immunogenicity ceiling — pre-existing anti-AAVrh74 antibodies exclude a slice of patients and cap redosing. Names or it didn't happen: the concrete named external dependencies are Stanford (IP origin), AAVrh74 (Sarepta-validated capsid), and Kite/Gilead (platform partner).
Real, but narrow and early.
Where the moat is thin: AAVrh74 is not proprietary; the epigenetic-silencing-of-DUX4 concept is published academically (dCas9-KRAB, dSaCas9 approaches exist in the literature and in others' patents ); and durability of epigenetic silencing in post-mitotic muscle is scientifically unproven long-term. The moat is "first + smallest + on-mechanism," not "unassailable."
n/a — pre-revenue, no reportable segments. There is no revenue to break out by product or geography. The economically meaningful "segmentation" is the pipeline by therapeutic area (captured in Lens 5) and the owned-asset vs. platform-partnership split of value:
n/a — private, not disclosed.+clinical overlay: Pipeline / Catalysts / Traction replace Earnings / Comps / Forecast)The asset table is the company:
| Program | Indication | Target / mechanism | Modality | Stage | Next catalyst |
|---|---|---|---|---|---|
| EPI-321 | FSHD | Silence DUX4 via epigenetic repression; restore D4Z4 methylation | GEMS + AAVrh74, single in-vivo dose | Phase 1/2 (NCT06907875), dosing | WMS Congress Sep 2026 (6 more pts); primary completion mid-2027 |
| EPI-331 | Duchenne MD (DMD) | Undisclosed (neuromuscular) | GEMS, in vivo | Research | IND-enabling (unspecified) |
| EPI-141 | Retinitis Pigmentosa 4 (RP4) | Undisclosed (ophthalmology) | GEMS, in vivo | Research | — |
| Undisclosed | Undisclosed | "silence + replace with wild-type" | GEMS, in vivo | Research | — |
| Kite/Gilead partnership | Blood cancers (CAR-T) | Modulate Kite-selected genes | GEMS constructs | Partner-run research | Milestone-gated |
EPI-321 latest data (the whole story — data cutoff May 12, 2026, released Jun 26, 2026):
Read: this is a genuinely positive early signal — muscle growth (not just slowed decline) plus a biomarker moving the right way plus clean safety, in a disease with no approved therapy. It is also n=3 at the efficacy timepoint, open-label, no control arm, no DUX4-in-muscle-biopsy silencing % disclosed yet. Encouraging, not dispositive.
Catalyst calendar:
| When | Event | Why it matters |
|---|---|---|
| Sep 2026 | World Muscle Society Congress — 6 additional patients | Does the muscle-volume signal replicate beyond n=3, and hold at higher dose? First real de-risking / de-railing point. |
| ~2026–2027 | Next private financing (Series B was a "first close" — see Lens 11) | Cash runway to primary completion; valuation mark. |
| Mid-2027 | EPI-321 Phase 1/2 primary completion + full readout | The value-inflection event. Powered function + durability. |
Mechanism comps (by target/approach, NOT by P/E — this is pre-revenue):
| Company | Asset | Mechanism | Stage vs. Epic | Threat level |
|---|---|---|---|---|
| Avidity Biosciences | del-brax (delpacibart braxlosiran) | siRNA (AOC) knockdown of DUX4 | Ahead — FDA-aligned on accelerated + full approval paths | Highest — likely first-to-market; chronic dosing but proven knockdown |
| Fulcrum Therapeutics | losmapimod | p38 MAPK inhibitor (indirect DUX4) | Mixed history (prior Ph3 miss); Sanofi ex-US deal up to $1B | High — oral, but not on-mechanism |
| Dyne Therapeutics | DYNE-302 | siRNA (FORCE) DUX4 knockdown | Clinical | High |
| Roche | RG-6237 / GYM-329 | anti-myostatin (muscle mass) | Clinical | Medium — different axis, could combine |
| Novartis / Kate Therapeutics | miRNA vs DUX4 (AAV) | AAV-miRNA gene therapy | Acquired for up to $1.1B (Nov 2024) | High — the closest one-time AAV analog, now Novartis-funded |
| aTyr, miRecule | various | various | earlier | Low-Med |
The comp verdict: Epic's EPI-321 is the only one-time epigenetic-silencing entrant, which is its differentiation — but it is entering a crowded, well-capitalized FSHD field where the two most advanced assets (Avidity, Fulcrum) are ahead and better funded, and the closest modality analog (AAV-based DUX4 knockdown) is now owned by Novartis. Epic is scientifically distinctive but strategically late and small.
+private re-point: founder/CEO messaging, not earnings calls)A pre-revenue private has no earnings calls to trend, so this lens tracks the public communication signal instead — the PR/data cadence and how management's framing has shifted:
No public equity, so "catalysts" = the private value-marking events:
Unusually strong for a company this size — a scientist-founder + a proven drug-development CEO.
Capital-allocation read: rational and disciplined for the stage — raised in tranches (A → partnership non-dilutive capital → B "first close"), prioritized one lead indication to a clinical readout rather than spreading thin, and pulled in venture-philanthropy (SOLVE FSHD) that aligns a mission-driven, patient-community backer. No value-destruction signals visible. Red flags: none material in public sources — the standard private-biotech caveats apply (unaudited; comp/related-party detail undisclosed; single-asset concentration is a strategy risk, not a governance one).
Forensic (accounting): n/a — private, pre-revenue, unaudited. There is no income statement, balance sheet, or cash-flow statement in the public domain and none in the research layer — so revenue-recognition, receivables/inventory, SBC-flattering-non-GAAP, and goodwill analyses are not applicable. The only "books" signals available are burn vs. runway (below) and they are estimates. This absence is itself the point for an investor: you are underwriting an unaudited private on management + data, not financials.
Regulatory findings:
"Epic Bio" / "Epicrispr" enforcement / consent decree / settlement / fine: no material adverse regulatory or enforcement hits found. FDA interactions to date are favorable (IND cleared Apr 2025; active Phase 1/2 under NCT06907875).n/a — no 10-K exists (private).Science-and-exclusivity sub-section (+clinical):
No EPS to forecast (pre-revenue). Two questions instead: does cash reach the next value-inflection catalyst, and what is the lead asset worth risk-adjusted?
Runway-to-catalyst: Series B was explicitly a "first close" of $68M (Mar 2025) — signaling more Series B capital was expected. Total raised ~$123M. At a ~43-person clinical-stage gene-therapy burn (call it ~$40–55M/yr ), the Series B funds roughly 12–18 months of trial execution — i.e. to around the Sep-2026 data / into 2027, but likely NOT all the way through mid-2027 primary completion without additional capital. The next financing (Series B extension / Series C / partnering) is itself a 2026–2027 catalyst and a risk. The Jun-2026 positive readout materially helps that raise.
rNPV of EPI-321:
+private write-back: no private-watch.json entry exists to update — flagged for Connor to seed one (stage: clinical-Phase1/2, ipo_readiness: low (single-asset, needs mid-2027 readout), catalyst: WMS Sep-2026 / primary mid-2027).(No forecast.ts create — per --watchlist rule, and there is no committed EPS/binary base case worth logging cold on n=3.)
Bull case. Epic has produced the first human evidence that an epigenetic editor can grow muscle in a degenerative disease — every treated-and-evaluable patient gained lean muscle volume, with a DUX4-pathway biomarker normalizing and clean early safety, all from a single dose. If that replicates at WMS (Sep 2026) and holds to mid-2027, EPI-321 isn't just an FSHD drug — it is clinical validation of the GEMS platform, which then makes DMD (EPI-331), RP4 (EPI-141), and the Kite CAR-T economics real, and turns Epic into a partnering/M&A magnet in a field where Novartis paid $1.1B, Sanofi committed $1B, and Gilead is buying in-vivo platforms. On-mechanism ("restore the methylation FSHD destroyed"), non-cutting, reversible, one-and-done — the most elegant approach in the indication, run by a CEO who has sold gene-therapy companies before. The secular tailwind: epigenetic editing is the next wave after cut-CRISPR, and Epic is the only one with a positive muscle readout in humans.
Bear case (permanent-impairment risks). (1) It arrives last to a crowded market. Avidity (del-brax, FDA-aligned on accelerated approval) and Fulcrum (losmapimod, Sanofi-backed) are ahead; by the time EPI-321 could launch (~2029+), the FSHD standard of care may be set by a chronic-but-proven siRNA — and a one-time therapy has to beat installed efficacy, not a blank slate. (2) Single-asset, private, cash-hungry. ~$123M against a multi-year AAV program; the Series B was only a "first close." A weak WMS readout or a frozen financing market and the company is forced to partner from weakness or stall. (3) The "one-time" claim is unproven — epigenetic silencing durability in post-mitotic muscle over years is the open scientific question; if effect wanes (the modality is reversible by design), the entire differentiation collapses and it becomes an inferior repeat-dose therapy. Pre-mortem (18 months out, thesis broke): WMS Sep-2026 shows the muscle-volume signal was n=3 noise / didn't replicate at higher dose, OR a later AAV-immunogenicity / immunosuppression safety event emerged; the Series B extension came in flat or down; Avidity's del-brax got accelerated approval and locked the market; Epic pivoted to a distressed platform-licensing sale. Contrarian view the market may be missing: the biomarker + MRI target-engagement signal is more important than the FSHD commercial opportunity — the real prize is platform validation, and the market is under-crediting the DMD/RP4/Kite optionality while over-focusing on whether Epic "wins FSHD" (which it probably won't, commercially).
Multiples too high? n/a (private, no traded multiple). On rNPV, the ~$123M raised is roughly fair for the lead asset with platform optionality as upside — not obviously stretched.
Dismantling the bull case. Where it breaks: the entire equity value rests on one AAV asset with n=3 efficacy at 6 months, open-label, no control. Muscle-volume gains of ~0.8 lb by MRI are real but small and unblinded, and "lean muscle volume" is not a validated FSHD approval endpoint — regulators will want function (walk/lift/quality-of-life), which n=3 at 3 months cannot show. Concentration: ~100% of value is FSHD-EPI-321; a single dose-limiting toxicity, a single AAV-immune death (the field's recurring nightmare), or a non-replication at WMS impairs the whole company. The moat is weaker than bulls think: AAVrh74 is Sarepta's public capsid (no moat), epigenetic DUX4 silencing is published academically and patented by others (FTO litigation risk against far richer rivals), and reversibility — sold as a safety feature — is a durability liability for a "one-time" claim. Most dangerous competitor bulls underrate: Avidity. del-brax has FDA alignment on an accelerated pathway — it can be approved and entrenched before Epic finishes Phase 1/2, and chronic-dosing "downside" evaporates if it works and is on the market first; Novartis/Kate's AAV-miRNA is the same one-time modality with a $1.1B balance sheet behind it. Worst capital-allocation risk: none egregious, but a "first close" Series B on a single asset means the company is structurally a forced seller/raiser — leverage sits with the pharma partners. What must hold for today's private mark: WMS replicates, safety stays clean, durability holds to mid-2027, and a supportive financing/IPO window opens — four independent things. If growth/efficacy disappoints 20–30% (signal is n=3 noise), the rNPV of EPI-321 → near the option value of the platform alone, and the raise-to-date looks rich. Single scenario that permanently impairs: an AAV-related serious safety event at the higher dose cohort — plausible enough to underwrite explicitly given systemic AAV history.
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40.
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.